Status:
COMPLETED
Study Comparing the Safety and Efficacy of Intravenous CXA-201 and Intravenous Meropenem in Complicated Intraabdominal Infections
Lead Sponsor:
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Conditions:
Complicated Intra-abdominal Infection
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This is a Phase 3, multicenter, prospective, randomized, double-blind, double dummy study of CXA-201 Intravenous (IV) infusions (1500mg q8h) and metronidazole (500mg q8h) versus meropenem (1000mg q8h)...
Detailed Description
Approximately, 500 subjects will be enrolled into this study, randomized 1:1 to receive CXA-201 and metronidazole or comparator (meropenem). Subject participation will require a minimum commitment of ...
Eligibility Criteria
Inclusion
- Diagnoses of cIAI.
- Subject requires surgical intervention (e.g., laparotomy, laparoscopic surgery, or percutaneous draining of an abscess) within 24 hours of (before or after) the first dose of study drug.
Exclusion
- Simple appendicitis; acute suppurative cholangitis; infected necrotizing pancreatitis; pancreatic abscess; or pelvic infections.
- Complicated intraabdominal infection managed by staged abdominal repair (STAR), open abdomen technique including temporary closure of the abdomen, or any situation where infection source control is not likely to be achieved.
- Use of systemic antibiotic therapy for IAI for more than 24 hours prior to the first dose of study drug, unless there is a documented treatment failure with such therapy.
- Have a concomitant infection at the time of randomization, which requires non-study systemic antibacterial therapy in addition to IV study drug therapy. (Drugs with only gram-positive activity \[e.g., daptomycin, vancomycin, linezolid\] are allowed).
- Severe impairment of renal function (estimated CrCl \< 30 mL/min), or requirement for peritoneal dialysis, hemodialysis or hemofiltration, or oliguria (\< 20 mL/h urine output over 24 hours).
- The presence of hepatic disease at baseline.
- Considered unlikely to survive the 4 to 5 week study period.
- Any rapidly-progressing disease or immediately life-threatening illness (including respiratory failure and septic shock).
- Have a documented history of any moderate or severe hypersensitivity or allergic reaction to any β-lactam antibacterial (a history of a mild rash followed by uneventful re-exposure is not a contraindication to enrollment), including cephalosporins, carbapenems, penicillins, or ß-lactamase inhibitors, or metronidazole, or nitroimidazole derivatives.
- Women who are pregnant or nursing.
Key Trial Info
Start Date :
December 23 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 15 2013
Estimated Enrollment :
494 Patients enrolled
Trial Details
Trial ID
NCT01445678
Start Date
December 23 2011
End Date
October 15 2013
Last Update
November 16 2018
Active Locations (61)
Enter a location and click search to find clinical trials sorted by distance.
1
Springfield, Illinois, United States
2
Boston, Massachusetts, United States
3
Robbinsdale, Minnesota, United States
4
Columbus, Ohio, United States